Valentino Michael A, Colon-Gonzalez Francheska, Lin Jieru E, Waldman Scott A
Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 132 South 10th Street, 1170 Main, Philadelphia, PA 19107, USA.
Expert Rev Endocrinol Metab. 2010 Sep 1;5(5):765-783. doi: 10.1586/eem.10.33.
With the eruption of the obesity pandemic over the past few decades, much research has been devoted to understanding the molecular mechanisms by which the human body regulates energy balance. These studies have revealed several mediators, including gut/pancreatic/adipose hormones and neuropeptides that control both short- and long-term energy balance by regulating appetite and/or metabolism. These endogenous mediators of energy balance have been the focus of many anti-obesity drug-development programs aimed at either amplifying endogenous anorexigenic/lipolytic signaling or blocking endogenous orexigenic/lipogenic signaling. Here, we discuss the efficacy and safety of targeting these pathways for the pharmacologic treatment of obesity.
在过去几十年肥胖症大流行爆发之际,大量研究致力于了解人体调节能量平衡的分子机制。这些研究揭示了几种介质,包括肠道/胰腺/脂肪激素和神经肽,它们通过调节食欲和/或新陈代谢来控制短期和长期能量平衡。这些能量平衡的内源性介质一直是许多抗肥胖药物研发项目的重点,这些项目旨在增强内源性厌食/脂解信号或阻断内源性食欲/脂肪生成信号。在此,我们讨论针对这些途径进行肥胖症药物治疗的疗效和安全性。